^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
Labcorp® Plasma Complete™

Company:
LabCorp
Type:
Laboratory Developed Test
Related tests:
Evidence

News

16d
Impact of genomic alterations measured in circulating tumor DNA (ctDNA) on clinical response to telisotuzumab vedotin treatment in patients with non-small cell lung cancer (NSCLC) (AIOM 2024)
METamp occurred more frequently in responders; but Teliso-V activity wasn’t restricted to these pts: most responders weren’t METamplified. Specific genomic alts beyond MET may influence clinical response. The current analysis demonstrated numeric differences between pts with identified drivers who did or didn’t respond to Teliso-V.
Clinical • Circulating tumor DNA
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
KRAS G12C • MET amplification • KRAS G12
|
Labcorp® Plasma Complete™
|
telisotuzumab vedotin (ABBV-399)
6ms
Labcorp to Present Multiple Abstracts across Precision Oncology at the 2024 ASCO Annual Meeting (PRNewswire)
"Labcorp researchers performed comprehensive genomic and immune profiling on 143 formalin-fixed paraffin-embedded breast cancer samples to investigate the interaction between VEGF and immune gene expression. In triple-negative breast cancer (TNBC) samples, VEGF was co-expressed with immune checkpoint genes such as PD-1 and PD-L1...Labcorp researchers performed a targeted RNA-sequence-based assay on 143 breast cancer patient samples, demonstrating that concurrent loss of HLA class I with increased HLA class II expression was associated with co-expression of biomarkers indicative of immune escape but not survival outcomes...Researchers analyzed genomic and gene expression data from over 2,000 colorectal cancer samples to generate and test a model for predicting MSI status, which was confirmed using MSI status from The Cancer Genome Atlas (TCGA) studies of colorectal and endometrial carcinoma."
Clinical data
|
Labcorp® Plasma Complete™
7ms
ctDNA analysis of patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib (LEN) or sorafenib (SOR) as 1L therapy. (ASCO 2024)
TERT, TP53, and CTNNB1 MUT had little effect on tumor response in either treatment arm; TP53 MUT appeared to be a factor for poor OS prognosis in both arms. Further analysis is needed due to the differences in baseline characteristics between ctDNA and ITT pts, and the difference in sample size between arms.
Clinical • Circulating tumor DNA
|
TP53 (Tumor protein P53) • CTNNB1 (Catenin (cadherin-associated protein), beta 1)
|
Labcorp® Plasma Complete™
|
sorafenib • Lenvima (lenvatinib)
7ms
Analytical validation of the Labcorp Plasma Complete test to enable precision oncology through solid tumor liquid biopsy comprehensive genomic profiling. (ASCO 2024)
The analytical validation of the Labcorp Plasma Complete test demonstrates that the liquid biopsy approach is highly sensitive, specific, accurate, reproducible, and robust for comprehensive genomic profiling to complement tissue-based testing and inform clinical decision making.
Liquid biopsy • Biopsy
|
MSI (Microsatellite instability)
|
Labcorp® Plasma Complete™
9ms
Enhanced detection of ctDNA molecular response for immunotherapy treated non-small cell lung cancer through analyses of cell-free and matched white blood cell DNA (AACR 2024)
This real-world study of ICI treated, advanced NSCLC highlights the opportunity afforded through integrated analyses of ctDNA and matched WBCs to accurately determine mR and the associations with radiographic response and OS.
Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker • Circulating tumor DNA
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
|
Labcorp® Plasma Complete™
over1year
Impact of genomic alterations measured in circulating tumor DNA (ctDNA) on clinical response to telisotuzumab vedotin treatment in patients with non-small cell lung cancer (NSCLC). (ASCO 2023)
MET amp occurred more frequently in responders; however, Teliso-V activity was not restricted to these pts, as most responders were not MET amplified. Specific genomic alterations beyond MET may influence clinical response. The current analysis demonstrated numeric differences between pts with identified drivers who did or did not respond to Teliso-V.
Clinical • Circulating tumor DNA
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
KRAS G12C • MET amplification • EGFR wild-type • MET overexpression • MET mutation • KRAS G12
|
Labcorp® Plasma Complete™
|
telisotuzumab vedotin (ABBV-399)
over1year
Enhanced detection and classification of cell-free DNA alterations through matched normal analyses with PGDx elioTM plasma complete (AACR 2023)
Additional sources of discordance for somatic and germline alterations were primarily attributed to patients with high levels of ctDNA where differentiation of these variant sources can be challenging through solely computational-based techniques. Taken together, these data demonstrate that through the integrated analysis of cell-free DNA and matched leukocyte DNA, classification of the source of cfDNA-derived alterations can be achieved, which may improve the accuracy of non-invasive tumor profiling, molecular response assessment, and clonal evolution analyses.
Tumor mutational burden
|
TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
|
Labcorp® Plasma Complete™
over2years
Comprehensive liquid biopsy profiling enabled by PGDx elio plasmacomplete to facilitate precision oncology through decentralized access to testing (AACR 2022)
The PGDx elio plasma complete assay can be processed manually or through automated liquid handling systems with high concordance, with an overall success rate of 97.8%. Taken together, these data demonstrate that the PGDx elio plasma complete assay is a sensitive, specific, accurate, reproducible, and robust approach to enable CGP to guide both translational biomarker discovery and CGP-informed precision oncology strategies.
Tumor mutational burden • BRCA Biomarker • Liquid biopsy
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • FGFR1 (Fibroblast growth factor receptor 1) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
|
Labcorp® Plasma Complete™
3years
Personal Genome Diagnostics and Cleveland Clinic Collaborate to Expand Utility of Liquid Biopsy Applications in Oncology Clinical Research (Personal Genome Diagnostics Press Release)
“Personal Genome Diagnostics…announced a collaboration with the Center for Immunotherapy and Precision Immuno-Oncology (CITI) and the Cleveland Clinic Lerner Research Institute, Cleveland, Ohio. Both parties will collaborate to enhance capabilities within elioTM plasma complete reporting, as well as collaborate on the development of proprietary methods for complex biomarker detection and assay iterations to meet emerging liquid biopsy applications in solid tumors. This strategic collaboration combines Cleveland Clinic’s world-class research and commitment to innovation with the comprehensive PGDx portfolio and actionable genomic information. Both organizations are driven to elevate the standard of care for patients and increase utilization of precision diagnostics within the cancer care continuum.”
Licensing / partnership
|
Labcorp® Plasma Complete™
over3years
Personal Genome Diagnostics launches elio™ plasma complete, a kit enabling decentralized, comprehensive liquid biopsy analysis for oncology research applications (Personal Genome Diagnostics Press Release)
"Personal Genome Diagnostics Inc. (PGDx)...today announced the launch of elio™ (empowering local insight for oncology) plasma complete, a NGS kit solution for comprehensive blood-based genomic analysis. The elio™ plasma complete kit is intended to support research in areas like biomarker discovery, therapy selection, and monitoring, and is ideal for investigating genetic mutations and genomic signatures in multiple cancer types."
Launch
|
Labcorp® Plasma Complete™